ATAI Life Sciences NV (ATAI)
1.36
+0.01
(+0.74%)
USD |
NASDAQ |
Nov 14, 16:00
1.50
+0.14
(+10.29%)
After-Hours: 20:00
ATAI Life Sciences Enterprise Value: 157.38M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 157.38M |
| November 12, 2024 | 175.84M |
| November 11, 2024 | 195.97M |
| November 08, 2024 | 167.45M |
| November 07, 2024 | 157.38M |
| November 06, 2024 | 128.85M |
| November 05, 2024 | 112.07M |
| November 04, 2024 | 112.07M |
| November 01, 2024 | 112.07M |
| October 31, 2024 | 108.72M |
| October 30, 2024 | 118.79M |
| October 29, 2024 | 122.14M |
| October 28, 2024 | 135.57M |
| October 25, 2024 | 122.14M |
| October 24, 2024 | 122.14M |
| October 23, 2024 | 133.89M |
| October 22, 2024 | 145.63M |
| October 21, 2024 | 132.21M |
| October 18, 2024 | 145.63M |
| October 17, 2024 | 132.21M |
| October 16, 2024 | 133.89M |
| October 15, 2024 | 113.75M |
| October 14, 2024 | 115.43M |
| October 11, 2024 | 115.43M |
| October 10, 2024 | 112.07M |
| Date | Value |
|---|---|
| October 09, 2024 | 113.75M |
| October 08, 2024 | 120.46M |
| October 07, 2024 | 118.79M |
| October 04, 2024 | 125.50M |
| October 03, 2024 | 108.72M |
| October 02, 2024 | 113.75M |
| October 01, 2024 | 118.79M |
| September 30, 2024 | 125.50M |
| September 27, 2024 | 127.18M |
| September 26, 2024 | 130.53M |
| September 25, 2024 | 128.85M |
| September 24, 2024 | 128.85M |
| September 23, 2024 | 132.21M |
| September 20, 2024 | 135.57M |
| September 19, 2024 | 142.28M |
| September 18, 2024 | 138.92M |
| September 17, 2024 | 145.63M |
| September 16, 2024 | 142.28M |
| September 13, 2024 | 148.99M |
| September 12, 2024 | 137.24M |
| September 11, 2024 | 140.60M |
| September 10, 2024 | 140.60M |
| September 09, 2024 | 138.92M |
| September 06, 2024 | 130.53M |
| September 05, 2024 | 135.57M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-58.73M
Minimum
Mar 22 2023
2.942B
Maximum
Jun 21 2021
457.98M
Average
187.05M
Median
Oct 18 2022
Enterprise Value Benchmarks
| Affimed NV | 30.82M |
| InflaRx NV | 20.31M |
| BioNTech SE | 8.336B |
| Immatics NV | 314.32M |
| CureVac NV | 394.66M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -57.31M |
| Revenue (Quarterly) | 0.273M |
| Total Expenses (Quarterly) | 25.62M |
| EPS Diluted (Quarterly) | -0.36 |
| Profit Margin (Quarterly) | -20.99K% |
| Earnings Yield | -28.68% |
| Normalized Earnings Yield | -50.22 |